A5027363796- Bone health and treatments
- Bladder and Urothelial Cancer Treatments
- Cancer Cells and Metastasis
- Urinary and Genital Oncology Studies
- Cancer, Hypoxia, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Breast Cancer Treatment Studies
- Prostate Cancer Treatment and Research
- Cytokine Signaling Pathways and Interactions
- Angiogenesis and VEGF in Cancer
- Colorectal Cancer Screening and Detection
- Urological Disorders and Treatments
- Multiple Myeloma Research and Treatments
- Retinoids in leukemia and cellular processes
- Immunotherapy and Immune Responses
- Ferroptosis and cancer prognosis
- Estrogen and related hormone effects
- Click Chemistry and Applications
- Microtubule and mitosis dynamics
- Bone Metabolism and Diseases
- Cancer Mechanisms and Therapy
- TGF-β signaling in diseases
- Cancer Diagnosis and Treatment
Sheffield Hallam University
2024
University of Sheffield
2015-2024
Weston Park Cancer Centre
2021
Duke University
2017
University of Lincoln
2017
Abstract The GUSTO clinical trial (Gene expression subtypes of Urothelial carcinoma: Stratified Treatment and Oncological outcomes) uses molecular to guide neoadjuvant therapies in participants with muscle‐invasive bladder cancer (MIBC). Before commencing the trial, we needed determine reliability a commercial subtyping platform (Decipher Bladder; Veracyte) when performed an external laboratory as this has not been done previously. Here, report our pre‐trial verification TCGA model using...
Abstract Breast cancer bone metastasis is currently incurable, ~75% of patients with late-stage breast develop disease recurrence in and available treatments are only palliative. We have previously shown that production the pro-inflammatory cytokine interleukin-1B (IL-1B) by cells drives preclinical vivo models. In current study, we investigated how IL-1B from tumour microenvironment interact to affect primary growth through regulation immune system, whether targeting IL-1 driven changes...
We report NHS England data for patients with bladder cancer (BC), upper tract urothelial (UTUC: renal pelvic and ureteric), urethral cancers from 2013 to 2019.
Metastatic recurrence in breast cancer is a major cause of mortality and often occurs many years after removal the primary tumour. This process driven by reactivation disseminated tumour cells that are characterised mitotic quiescence chemotherapeutic resistance. The ability to reliably isolate characterise this cell population critical enable development novel therapeutic strategies for prevention recurrence. Here we describe identification characterisation sub-population slow-cycling MCF-7...
Excessive production of Transforming Growth Factor β (TGFβ) is commonly associated with dominant and recessive forms OI. Previous reports have indicated that administration TGFβ-targeted antibodies maybe potential therapeutic benefit to OI patients. However, direct targeting TGFβ likely cause multiple adverse effects including simulation autoimmunity. In the current study we use patient-derived normal fibroblasts, osteoblasts OIM mouse models determine Losartan, an angiotensin II receptor...
TPS4621 Background: Muscle invasive bladder cancer (MIBC) is an aggressive disease with poor survival rates that are not improving. Curative treatment includes systemic neoadjuvant chemotherapy prior to radical cystectomy and adjuvant immunotherapy. However, many patients do respond or Histologically similar MIBCs can be classified using gene expression patterns into unique molecular subtypes. Retrospective studies have shown subtypes each biology consequently differently treatment. The...
Components of the mitochondrial electron transport chain have recently gained much interest as potential therapeutic targets. Since mitochondria are essential for supply energy that is required both angiogenic and tumourigenic activity, targeting represents a promising approach treating cancer. Here we investigate established anti-angiogenesis drugs combretastatin A4, thalidomide, OGT 2115 tranilast hypothesise able to exert direct anti-cancer effect in absence vasculature by mitochondria....
Metastatic recurrence, the major cause of breast cancer mortality, is driven by reactivation dormant disseminated tumour cells that are defined mitotic quiescence and chemoresistance. The molecular mechanisms underpinning in poorly understood, severely limiting development novel therapies for removal residual, metastasis-initiating cells. Here, we present a portrait quiescent cell transcriptome across four main sub-types (luminal, HER2-enriched, basal-like claudin-low) identify...
Abstract Novel therapeutic strategies to eliminate chemo-resistant tumour cells responsible for the development of secondary lesions are essential in order prevent breast cancer relapse. We have developed an vitro model system enabling isolation a putative metastasis-initiating cell sub-population with mitotically quiescent, drug-resistant phenotype. hypothesise that this population is able utilise oestrogen-related receptor-alpha (ERR-α)-regulated oxidative lactate metabolism and inhibition...